Capital Boost for Regenerative Repair Material Platform
Medgen Life Science (Shenzhen) Co., Ltd. has successfully completed its Series A financing round of tens of millions of RMB, exclusively invested by Huaxi Yuanyou Fund. The proceeds will be used to drive continued innovation in the company's regenerative repair material product pipeline, clinical research, and commercialization efforts, further solidifying Medgen's leading position in multi-disciplinary regenerative repair across medical aesthetics, orthopedics, and sports medicine.
Regenerative Repair: A Multi-Billion-RMB Market with Rising Penetration
China's bone repair materials market is projected to reach RMB 9.69 billion in 2023, with a five-year CAGR of 19.8% — far exceeding global industry growth. With an annual net increase of 4.7 million unmet orthopedic cases and rising demand in medical aesthetics and dentistry, domestically produced high-biomimetic, cost-effective repair materials are poised for rapid adoption.
The mainstream direction in artificial bone repair materials is biomimetic composites that closely resemble natural human bone. These materials feature highly biomimetic composition and structure, excellent biocompatibility and osteoconductive capacity, with gradual creeping substitution by new bone tissue during the regeneration process, ultimately achieving complete homologous integration with degradation rates matching new bone formation.
Medgen's independently developed next-generation osteoinductive bone repair material series is China's first injectable artificial bone. Compared to existing PLA/PLGA/hydroxyapatite-based artificial bone products on the market, it offers easier handling and superior biological performance including osteoconduction. It is indicated for filling bone defects and gaps in low-load-bearing extremities and spine. In preliminary exploratory large-animal spinal fusion experiments, the material demonstrated excellent osteoinductive properties comparable to autologous bone.
Rotator cuff tears are among the most common tendon injuries in orthopedics and sports medicine, representing a major clinical challenge. Currently, no rotator cuff patch products have been approved for market in China — an unmet need. Medgen's proprietary composite rotator cuff patch addresses the existing limitations of insufficient mechanical strength and immune rejection risk, demonstrating excellent repair outcomes. This project has been designated a Shenzhen municipal key technology initiative.
In the light medical aesthetics filler market, injectable agents represent an existing market of over RMB 10 billion with high technical barriers. New regenerative injectable products can achieve billion-level sales within 2-3 years of launch. While superior hydroxyapatite-based products are widely used internationally, the Chinese market for hydroxyapatite-based regenerative injectables remains a blue ocean.
Driven by the trend of pursuing natural beauty, regenerative materials promote the body's own fibroblast and collagen regeneration to achieve facial rejuvenation. Compared to traditional fillers with shorter duration, regenerative materials offer natural, progressive, and long-lasting results — marking the industry's transition from the era of pure filling to the era of regeneration.
With its multi-material, multi-technology portfolio and rich product pipeline, Medgen Life Science is well positioned to meet the rapid iteration and market segmentation demands of the medical aesthetics industry.
Medgen Life Science: A Self-Developed Materials Platform Across Multiple Fields
Medgen is a supplier of natural porous hydroxyapatite repair materials and long-chain triple-helix collagen protein materials, serving orthopedics, sports medicine, dentistry, and medical aesthetics — a comprehensive Class III medical device company. The company operates a 10,000+ square meter production facility and R&D center in Shenzhen, maintains over ten university-hospital collaboration projects, and holds more than 40 independent intellectual property rights. It is recognized as a national technology-based SME and National High-Tech Enterprise.
Medgen focuses on novel regenerative materials, providing self-developed next-generation repair and filling materials with superior biocompatibility to address clinical pain points across multiple scenarios. Specializing in animal-derived extraction with full proprietary processing technology, the company has established a platform spanning medical aesthetics, orthopedics, sports medicine, and dentistry.
On the raw material side, the company maintains upstream supply chain control to ensure stable, consistent, and compliant sourcing. On the processing side, it commands the full suite of pre-processing technologies to ensure clinical trial and product supply safety in compliance with national regulations. The company's two core technology platforms — hydroxyapatite regenerative product conversion and biomedical collagen crosslinking technology — deliver full-chain regenerative biomaterial solutions.
The founding team combines decades of deep experience in biomedical materials, drawing from top academician research groups and rich domestic clinical resources. With over ten years at renowned domestic and international companies, the team brings extensive experience in Class III and Class II medical device R&D, clinical research, quality production operations, and sales and management across medical aesthetics, orthopedics, and sports medicine.
The company is methodically advancing its R&D, market, and sales initiatives. Next steps include progressing clinical research for medical aesthetics and sports medicine products; orthopedic products are expected to receive regulatory approvals and launch in the near term. Going forward, the company will maintain balanced, rapid development across both serious medicine and consumer healthcare.
Stakeholder Perspectives
Company Founder and CEO Deng Siling stated: "We are deeply grateful for Huaxi Yuanyou Fund's confidence in Medgen and Changhai Capital's outstanding support in this financing round. Regenerative repair materials represent enormous global market potential. Over the years, Medgen has been deeply committed to R&D and translation of tissue regenerative repair products. Through real, effective clinical feedback, we have successfully developed regenerative repair products that improve patient health and meet aesthetic needs in orthopedics and medical aesthetics. With investor support, we will continue to uphold our product strengths, advance our technologies, and further drive the development of regenerative repair."
Liang Shuang, Partner at Huaxi Yuanyou Fund stated: "Hydroxyapatite has a long history of application as a medical raw material. Natural porous hydroxyapatite has unique advantages in tissue repair, filling, and induction of regeneration. Meanwhile, Chinese consumers of medical aesthetics have developed relatively mature market awareness of regenerative preparations based on hydroxyapatite. Medgen's R&D pipeline centered on natural materials, including porous hydroxyapatite and collagen, meets the expectations of the compliant consumer market and will certainly gain broad market recognition in the field of regenerative medicine."
About Huaxi Yuanyou Fund: Hainan Huaxi Yuanyou Fund is a RMB 1 billion industry investment fund jointly established by Huaxi Biologicals, Landsea & Hana, Hainan Free Trade Port Fund, and Haikou National High-Tech Zone Fund. It is the first equity investment fund initiated by Huaxi Biologicals for the incubation of start-ups in the healthcare consumer products sector.